Welcome to our dedicated page for Galmed Pharmaceu SEC filings (Ticker: GLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galmed Pharmaceuticals Ltd. (GLMD) SEC filings page on Stock Titan compiles the company’s U.S. regulatory disclosures, with AI-assisted summaries to help interpret the information. As a foreign private issuer listed on The Nasdaq Capital Market, Galmed furnishes reports on Form 6-K and files an annual report on Form 20-F, detailing its clinical programs, financial position and key risks.
For a clinical-stage biopharmaceutical company focused on Aramchol, filings provide context on research and development spending, net losses, cash, short-term deposits and marketable securities, all of which are central to assessing funding for liver, GI oncology and cardiometabolic studies. Interim condensed consolidated financial statements, included in 6-K submissions for periods such as the three and six months or three and nine months ended on specific dates, outline operating expenses, financial income, impairment charges and changes in stockholders’ equity.
Galmed’s 6-K filings also frequently attach press releases as exhibits, covering topics like AM-001 bioavailability results for Aramchol meglumine, top-line findings from oncology mechanism-of-action studies, new use patents for Aramchol combinations, quarterly financial results and adoption of a digital asset management strategy. Other 6-Ks document corporate actions, including notices and outcomes of shareholder meetings and amendments to the Articles of Association to increase authorized share capital.
On this page, users can quickly access Galmed’s 20-F annual report for a comprehensive discussion of risk factors, business overview, and detailed financial statements, and review successive 6-Ks for updates between annual filings. Stock Titan’s AI tools highlight key points from lengthy documents, helping readers understand how Galmed describes the development of Aramchol for liver disease, GI cancers and cardiometabolic indications, as well as how it discloses treasury policies such as its crypto-related strategy.
Galmed Pharmaceuticals Ltd. files its Form 20-F annual report for the year ended December 31, 2025, detailing continued operating losses and substantial doubt about its ability to continue as a going concern.
The company is refocusing lead drug Aramchol from NASH and fibrosis toward oncological and cardiometabolic indications, while acknowledging it has no approved products and limited commercialization experience. For 2024 and 2025, losses attributable to ordinary shareholders were approximately $7.5 million and $10.3 million, respectively, leading to an accumulated deficit of $210.8 million as of December 31, 2025.
Galmed reports net working capital of $15.8 million, including $4.0 million in cash and cash equivalents, $7.1 million in short-term deposits and $7.0 million in marketable debt securities, which it currently expects to fund operations for more than 12 months. Management warns that additional capital will be required, highlights constraints under the Form F-3 Baby Shelf Rule, and discloses potential shareholder dilution from outstanding warrants, options and RSUs. The report emphasizes extensive clinical, regulatory, financing and market risks, including dependence on Aramchol, uncertainty in NASH regulatory pathways, reliance on third parties and exposure to geopolitical risk in Israel.
Galmed Pharmaceuticals Ltd. director David Sidransky filed an initial ownership report showing his equity position in the company. He directly holds 11,083 Ordinary Shares, along with several awards of Restricted Share Units (RSUs) that vest between 2026 and 2028, subject to his continued service.
The filing also lists stock options to purchase 111 Ordinary Shares at an exercise price of 558, expiring in 2031, and options on 166 Ordinary Shares at an exercise price of 2,080.8, expiring in 2028. The entry records holdings rather than new buy or sell transactions.
Galmed Pharmaceuticals Ltd. filed a Form 3 showing Chief Financial Officer Doron Leib Cohen’s existing equity holdings in the company. He directly holds 22,083 Ordinary Shares, several blocks of Restricted Share Units, and options to purchase 208 Ordinary Shares at an exercise price of 68.4000 per share expiring on February 23, 2032.
One RSU grant of 2,083 units vests on August 7, 2026, another of 23,333 units vests in four equal parts on May 12, 2026, November 12, 2026, May 12, 2027 and November 12, 2027, and a further RSU award of 25,000 units vests one-third on August 26, 2026 with the rest in four installments through August 26, 2028, all subject to his continued service.
Galmed Pharmaceuticals Ltd. director and CEO Baharaff Allen has filed an initial statement of holdings, detailing his equity position in the company. He directly owns 103,047 ordinary shares and has an additional 18 ordinary shares beneficially owned through his spouse.
He also holds options to purchase ordinary shares, including grants exercisable for 1,222 shares at exercise prices of 599.4000, 921.6000, and 2080.8000 per share, expiring between 2028 and 2030, plus options over 1,805 shares at an exercise price of 0.0020 per share expiring in 2028.
In addition, he reports restricted share units, including 8,889 units that vest on August 7, 2026, 96,666 units vesting in four equal installments between May 12, 2026 and November 12, 2027, and 100,000 units vesting between August 26, 2026 and August 26, 2028, all subject to his continued service. The filing reflects holdings only and does not show new buy or sell transactions.
Galmed Pharmaceuticals Chief Accounting Officer Yohai Stenzler filed an initial ownership report showing direct holdings of 22,116 Ordinary Shares of GLMD. He also holds several equity awards and options that may convert into additional shares over time.
The filing lists options to purchase Ordinary Shares with an exercise price of 68.4000 per share, covering 222, 222, 111 and 222 underlying shares expiring between 2027 and 2030. Restricted share units include 2,083 units vesting on August 7, 2026, 23,333 units vesting in four installments from May 12, 2026 through November 12, 2027, and 25,000 units vesting between August 26, 2026 and August 26, 2028, all subject to his continued service.
Galmed Pharmaceuticals Ltd. Chief Scientific Officer Liat Nissimov Brueck filed an initial statement of beneficial ownership, reporting direct holdings of employee stock options. These options allow her to purchase Ordinary Shares at an exercise price of 68.4000 per share, with individual grants covering 222, 181 and 153 underlying shares. The options have staggered exercise and expiration dates ranging from 2016-09-06 to 2030-11-10, showing a series of long-term equity awards rather than new market transactions.
Galmed Pharmaceuticals Chief Operating Officer Nehemya Guy filed an initial ownership report showing his equity stake in the company. He directly owns 22,116 Ordinary Shares, along with stock options and multiple restricted share unit (RSU) awards.
He holds three option grants to purchase Ordinary Shares, each covering 222 underlying shares at an exercise price of $68.40, with expiration dates in 2028, 2029, and 2030. In addition, he holds RSU awards covering 2,083, 23,333 and 25,000 shares that vest between 2026 and 2028, subject to his continued service.
Galmed Pharmaceuticals director Amir Poshinski has reported his initial ownership position in the company. The filing shows direct holdings of ordinary shares, multiple restricted share unit grants that vest over several dates through 2028, and stock options over 111 and 166 ordinary shares at exercise prices of 558.0000 and 2080.8000, expiring in 2031 and 2028 respectively.
Galmed Pharmaceuticals Ltd. director Carol L. Brosgart filed an initial ownership report showing she holds several option grants to purchase Ordinary Shares. The options have exercise prices ranging from 1.4100 to 2080.8000 and expiration dates from 2027-04-25 through 2035-10-29. Footnotes state that portions of these options vest in stages between 2026 and 2028, subject to her continued service.